Olindo Assis Martins-Filho
Overview
Explore the profile of Olindo Assis Martins-Filho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
287
Citations
2410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henriques P, Almeida G, Rimkute I, Dos Santos L, Liechti T, Marino A, et al.
Immunology
. 2025 Mar;
PMID: 40035468
Toxoplasma gondii is a highly versatile parasite that infects most warm-blooded animals and is a major cause of retinochoroiditis and uveitis in humans. The pathophysiology of these conditions remains poorly...
2.
Sartori N, Machado K, Miyamoto S, Pretti F, Gouveia M, de Oliveira Y, et al.
Vaccines (Basel)
. 2025 Feb;
13(2).
PMID: 40006674
Objective: To evaluate the humoral response to and impact of SARS-CoV-2 vaccination in patients with systemic lupus erythematosus in a multicenter cohort design. Methods: Data for this analysis were obtained...
3.
Capao A, Araujo M, Tort L, Toledo T, Oliveira A, Caetano B, et al.
Vaccine
. 2025 Feb;
50:126785.
PMID: 39938313
SARS-CoV-2 emerged rapidly as a pandemic, leading to the urgent development and authorization for the use of several vaccines, with questions relating to immunogenicity in previously infected people or to...
4.
Sasaki L, Canellas-de-Castro M, Fernandes G, Motta F, Araujo Junior D, de Araujo Junior D, et al.
Immunol Lett
. 2025 Feb;
274:106979.
PMID: 39933603
The present study intended to characterize the profile of soluble immune mediators in serum samples and in the cerebrospinal fluid (CSF) microenvironment from parturients with acute and convalescent COVID-19 as...
5.
McClure M, de Rezende I, Pereira L, Dutra M, Fradico J, Macedo R, et al.
Front Med (Lausanne)
. 2025 Feb;
12:1505005.
PMID: 39931562
Objective: To characterize the clinical manifestations of yellow fever disease and identify risk factors for mortality. Methods: A retrospective study was conducted in the referral center for infectious diseases (Hospital...
6.
Brito-de-Sousa J, Lima-Silva M, Costa-Rocha I, da Costa-Rocha I, Campi-Azevedo A, Mambrini J, et al.
Exp Gerontol
. 2025 Feb;
202:112700.
PMID: 39909312
Aging is associated with several physiological changes, including a remarkable remodeling of the immune system. Herein, the rhythms and shifts in serum immune mediators were characterized in a decade lifespan...
7.
Cardoso Correa-Dias L, Lopes-Ribeiro A, Marques-Ferreira G, Gomes-de-Pontes L, Pereira-Santos T, de Sousa Reis E, et al.
Immunogenetics
. 2025 Jan;
77(1):13.
PMID: 39890694
Several barriers for the development of an HCV vaccine still exist, including the genetic diversity of the virus, and the shortage of assessable models for in vitro and in vivo...
8.
Teixeira C, Dias J, Morgado-Santos L, da Costa-Rocha I, Giarola-Silva S, Lopes-Ribeiro A, et al.
Inflamm Res
. 2025 Jan;
74(1):16.
PMID: 39797999
Introduction: The present study aimed at evaluating the systemic profile and network connectivity of immune mediators during acute chikungunya fever (CHIKF) according to days of symptoms onset and ageing. Methods:...
9.
Machado K, Burian A, Martins-Filho O, Mill J, Ferreira L, Tapia K, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39772029
Background/objectives: The effectiveness of COVID-19 vaccine in patients with immune-mediated inflammatory diseases (IMID) depends on the underlying disease, immunosuppression degree and the vaccine regimens. We evaluate the safety and immunogenicity...
10.
Lanna M, Resende L, De Luca P, Goes W, Zaldivar M, Costa A, et al.
Vaccines (Basel)
. 2025 Jan;
12(12.
PMID: 39771984
Background/objectives: Considering the large number of candidates in vaccine-testing studies against different pathogens and the amount of time spent in the preclinical and clinical trials, there is a pressing need...